Dubai, U.A.E. – Over the next decade, there will be a shift in digital pathology and artificial intelligence (AI) applications from the pharmaceutical sector to clinical diagnostics. Once they are established as primary and secondary diagnostic tools, clinicians will be able to decrease turnaround time, prioritize critical cases, and improve overall patient outcomes. However, for AI tools to gain regulatory approval for primary diagnosis in digital pathology, it is imperative to adopt a parallel workflow to showcase the superior benefits of pathology diagnoses that amass data.
"AI has the potential to analyze big data and find patterns and insights that could enhance patient outcomes in the field of pathology,” said Deepak Jayakumar, Senior Research Analyst, TechVision. "It can serve as a supplementary or a validation tool in imaging analytics for pathologists, and help process more slides in a shorter duration." So far, AI-based medical diagnostic tools like OsteoDetect have already been approved for use by the FDA for the detection of distal radius fracture. Furthermore, AI-powered tools can better identify skin lesions and the presence of invasive breast cancer."
Frost & Sullivan’s recent analysis, Digital Pathology: Roadmap to the Future of Medical Diagnosis covers the solutions of digital whole slide scanning, digital imaging solutions, and digital data repository. The study identifies technology advancements, applications, and potential, as well as presents the most successful business models and strategies currently dominating the market.
For further information on this analysis, please click here.
"Hospitals and diagnostic labs will be the largest adopters of digital pathology over the next decade," noted Jayakumar. "Technology innovators can ensure greater commercialization by focusing on improving cost optimization for end users through pay-per-use or Software-as-a-Service (SaaS) models. Additionally, they could map service gaps, expand product portfolios, and use the information obtained from clinical data to develop cutting-edge solutions."
A few highlighted growth opportunities for digital pathology-enabling technology companies within this analysis include:
- Responsible use of datasets owned by medical institutions. A case in point is the creation of an imaging research warehouse by Mount Sinai Health System, which equips researchers with imaging and clinical data of more than a million patients.
- Collaboration with hospitals, diagnostic labs, and medical institutes to generate datasets comparing digital pathology and traditional methods to present a solid case for the regulatory approval of their product.
- Approval of AI-based tools needs to be a top priority for AI-based digital pathology-focused companies as low to medium risk diagnostic avenues are also an innovative way to transition from pharmaceutical to mainstream clinical applications in the digital pathology segment.
Digital Pathology: Roadmap to the Future of Medical Diagnosis is part of Frost & Sullivan’s global Medical Devices & Imaging Growth Partnership Service program.
Frost & Sullivan's global TechVision practice is focused on innovation, disruption and convergence and provides a variety of technology-based newsletters and research services as well as growth consulting services. Its premier offering, the Top 50 Technologies program, identifies and evaluates the most valuable emerging and disruptive technologies enabling products with near-term potential. A unique feature of the TechVision program is an annual selection of 50 technologies that can generate convergence scenarios, possibly disrupt existing business models, and drive transformational growth. View a summary of our TechVision program by clicking on the following link: http://ifrost.frost.com/TechVision_Demo.
-Ends-
About Frost & Sullivan
For over five decades, Frost & Sullivan has become world-renowned for its role in helping investors, corporate leaders and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models and companies to action, resulting in a continuous flow of growth opportunities to drive future success.
Media Contact:
Anita Chandhoke
Head – PR & Corporate Communications - MEA
P: +91 80 67028020
E: achandhoke@frost.com
Twitter: @Frost_Sullivan & @Frost_MENASA
Facebook: http://www.facebook.com/frostandsullivan
LinkedIn: https://www.linkedin.com/showcase/frost-&-sullivan-%E2%80%93-middle-east-north-africa-south-asia/
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
